AstraZeneca reports strong FY 2024 results with robust revenue growth driven by oncology and biopharmaceuticals

Pallavi Madhiraju- February 9, 2025 0

AstraZeneca’s financial performance for fiscal year 2024 reflects impressive growth, with the pharmaceutical giant reporting a 21% surge in total revenue, reaching $54.1 billion. This ... Read More

Roche secures FDA approval for HER2-ultralow metastatic breast cancer diagnostic

Pallavi Madhiraju- February 2, 2025 0

Roche has received FDA approval for an expanded use of its PATHWAY HER2 (4B5) test, marking a significant breakthrough in breast cancer diagnostics. This development ... Read More

ENHERTU gains FDA approval for HER2 low or ultralow metastatic breast cancer treatment

Pallavi Madhiraju- January 28, 2025 0

Daiichi Sankyo and AstraZeneca’s ENHERTU (fam-trastuzumab deruxtecan-nxki) has secured approval from the U.S. Food and Drug Administration (FDA) for treating adults with unresectable or metastatic ... Read More

Datroway approved in US: A new era in metastatic breast cancer treatment

Pallavi Madhiraju- January 19, 2025 0

In a landmark decision, the US Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan), a first-in-class TROP2-directed antibody-drug conjugate (ADC) developed by AstraZeneca ... Read More

AstraZeneca’s breakthrough in lung cancer treatment: Datopotamab deruxtecan achieves promising survival rates

Pallavi Madhiraju- September 9, 2024 0

AstraZeneca's datopotamab deruxtecan (Dato-DXd), a cutting-edge TROP2-directed antibody-drug conjugate, has demonstrated encouraging overall survival results in the TROPION-Lung01 Phase III trial, which focused on patients ... Read More

Datopotamab deruxtecan shows promise in Phase III trial for NSCLC

Pallavi Madhiraju- May 28, 2024 0

AstraZeneca and Daiichi Sankyo have announced promising results from the TROPION-Lung01 Phase III trial, highlighting datopotamab deruxtecan's potential as a treatment for advanced nonsquamous non-small ... Read More

ENHERTU receives EU approval for advanced non-small cell lung cancer

Pallavi Madhiraju- October 23, 2023 0

The European Union (EU) has given its nod to ENHERTU (trastuzumab deruxtecan) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) ... Read More

AstraZeneca and Daiichi Sankyo’s Enhertu recommended for EU approval

Pallavi Madhiraju- September 16, 2023 0

AstraZeneca and Daiichi Sankyo's Enhertu has been recommended for approval in the European Union (EU) for the treatment of adult patients with advanced non-small cell ... Read More

Patritumab Deruxtecan Phase 2 trial unveils encouraging outcomes in metastatic NSCLC

Pallavi Madhiraju- September 10, 2023 0

The HERTHENA-Lung01 Phase 2 trial, presented at the 2023 World Conference on Lung Cancer by Daiichi Sankyo, demonstrated that Patritumab Deruxtecan has potential for treating ... Read More

American Regent’s HEART-FID trial for INJECTAFER fails to meet primary endpoint

Pallavi Madhiraju- August 27, 2023 0

American Regent, Inc., a subsidiary of Daiichi Sankyo Group, has announced disappointing results from its phase 3 HEART-FID trial of INJECTAFER (ferric carboxymaltose injection) for ... Read More

1210 / 17 Posts